This page shows the latest lifitegrast news and features for those working in and with pharma, biotech and healthcare.
The transaction includes the Swiss drugmaker’s non-steroid, anti-inflammatory eye drop Xiidra (lifitegrast ophthalmic solution), which is specifically approved to treat the signs and symptoms of dry eye disease
Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Once fully rolled out, analysts have suggested lifitegrast could become a
All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast).
The Anglo-Irish company is making much of that fact that Xiidra (lifitegrast) - the first in a new class of lymphocyte function-associated antigen 1 (LFA-1) antagonist - is the only
The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic solution) is taken twice a day. ... says. Lifitegrast, which was licensed from SARcode Bioscience in 2013, is a
Additional data required before firm can apply for re-approval. Shire suffered a major setback last week when the FDA declined to approve its lifitegrast treatment for dry eye disease, which ... Lifitegrast is a small molecule integrin beta(2) antagonist
More from news
Approximately 3 fully matching, plus 6 partially matching documents found.
Shire's second acquisition of the month was also in the field of ophthalmology bringing SARcode Bioscience for $160m plus additional milestones with its phase III stage product Lifitegrast for dry ... Lifitegrast is a small-molecule integrin antagonist
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Blending brilliant writing with in-depth market access and reimbursement expertise...